Responsible for the development and execution of Translational strategies to advance Individualized Neoantigen Therapy in multiple solid tumor indications.

Responsible for the development and execution of Translational strategies across multiple clinical programs ranging from First-in-Human (FIH) to registrational studies to advance the Antibody-drug Conjugate (ADC) pipeline

• Responsible for the overarching strategies of Clinical Biomarker and CDx in solid tumor therapeutic area for 3 clinical-stage assets• Oversee biomarker-related activities to support the preclinical Immuno-Oncology therapeutic area

• Responsible for the overarching strategies of Clinical Biomarker and CDx in the IDH solid tumor therapeutic area• Oversee biomarker-related activities to support the preclinical Immuno-Oncology therapeutic area

• Lead the development, implementation, and execution of Clinical Biomarker strategies for IDH inhibitors (Ivosidenib and Vorasidenib) in early and late stage clinical development• Lead a cross-functional team to develop and execute CDx strategies• Serve as a core member of a clinical stage cross-functional project team responsible for strategy development and portfolio management• Design and execute biomarker-related activities to support preclinical Immuno-Oncology programs

Development of clinical biomarkers for cardiovascular and metabolic programs

Research areas: Cancer, Apoptosis, ER stress, Drug discovery• Work on cross-functional team for an early stage pipeline project focusing on developing small molecular inhibitors• Identify potential drug targets and regulation mechanisms by high-throughput RNAi screen• Assess the safety profiles of drug inhibition in preclinical models• Designed an ELISA assay and developed a cell reporter assay for RNAi and compound screen • Investigated therapeutic opportunities for target inhibition and combination therapies on multiple myeloma and triple negative breast cancer• Identified a potential predictive biomarker for apoptosis-based cancer therapy• Investigated mechanisms of anti-cancer drug resistance upon epithelial to mesenchymal transition (EMT)• Utilized siRNA screen, microarray, and proteomics for gene expression and pathway analysis• Lead multiple scientific projects and coordinate collaborations within GenentechPublications:Lu M*, Lawrence D*, Marsters S, Acosta-Alvear D, Kimmig P, Mendez SA, Paton AW, Paton JC, Walter P and Ashkenazi A (2014). Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 345, 98-101.Lu M, Marsters S, Ye X, Luis E, Gonzalez L and Ashkenazi A (2014). E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol. Cell 54, 987-998.Chang TK, Lawrence DA, Lu M, Tan J, Harnoss JM, Marsters SA, Liu P, Sandoval W, Martin SE and Ashkenazi A (2018). Coordination between two branches of the unfolded protein response determines apoptotic cell fate. Mol. Cell 16, 629-636.Harnoss JM,...Lu M,...Ashkenazi A (2019) Disruption of IRE1 through its kinase domain attenuates multiple myeloma. Proc. Natl. Acad. Sci. U.S.A.Nair P, Lu M, Petersen S and Ashkenazi A (2014). Apoptosis initiation through the cell extrinsic pathway. Methods Enzymol. 544, 99-128.